METROPOLIS

NextGen liqui CORE
Lung 12 gene Panel

Patient Selection	Technology	Specimen	Test Code	TAT
Metastatic Stage 3 & 4 NSCLC	Next Generation Sequencing	Blood	L8171	20 days

- cfTNA (Cell-free total nucleic acid- DNA & RNA) based assay that identifies clinically relevant genomic alterations within the 12 genes
- Validated on clinical research samples and detects somatic variants as low as 0.1% frequencies
- Sensitivity and specificity : >99%
- 100% concordance with ddPCR samples and Horizon controls results for SNVs and Short Indels

Alteration Type	Genes Covered
Coverage of 12 genes	ALK, BRAF, EGFR, ERBB2, KRAS, MAP2K1, MET, NRAS, PIK3CA, RET, ROS1, TP53
SNVs and Hotspots	>150 hotspots including: EGFR: T790M, C797S, L858R, Exon 19 del KRAS: G12X, G13X, Q61X BRAF: V600E ALK: Exon 21-25 PIK3CA: E545K, H1047R, E542K
CNVs	MET
Fusions	ALK, RET, ROS1
Extra	MET exon 14 skipping

METROPOLIS

NextGen liqui CORE
Lung 12 gene Panel

Specimen Type	
Serum	
Date & Time of Specimen Collection	Date & Time of Accessioning
20/02/2020	21/02/2020 11:57 Hrs

Case Number:

Patient Name:

Age/Sex:

Patient Location:

Hospital Name:

Physician Name:

Date & Time of Reporting:

Test Information

NextGen liqui CORE lung 12 gene panel is a Next Generation Sequencing (NGS) based assay that identifies clinically relevant genomic alterations within the 12 genes (ALK, BRAF, EGFR, ERBB2, KRAS, MAP2K1, MET, NRAS, PIK3CA, RET, ROS1 and TP53) that are most frequently altered in Non Small Cell Lung Cancer (NSCLC) (Detailed information has been provided in additional information section).

Specimen Information

Clinical History

Results

1 Genomic Finding

Variant Found: EGFR, Exon 19 deletion, p.Glu746_Ala750del
Variant Classification (AMP): Tier 1
Variant Classification (ACMG): Pathogenic

5 FDA Approved Therapy in NSCLC

Afatinib
Dacomitinib
Erlotinib
Gefitinib
Osimertinib

0 Off Label Suggestions with FDA Approval in another Indication

4 Clinical Trials

For more details, please refer to page 4

OTHER FINDINGS

No other clinically relevant mutation(s) was detected in the ALK, BRAF, ERBB2, KRAS, MAP2K1, MET, NRAS, PIK3CA, RET, ROS1 and TP53 genes for the index patient.